Listed

IGC Pharma, Inc.: Form 10-Q for the period ended Sep 30, 2016

Filed with the SEC on Nov 21, 2016 and accepted by EDGAR at Nov 21, 2016, 09:20 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2016-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2016-07-01 to 2016-09-30$162.2kus-gaap:Revenues
Revenue6 months2016-04-01 to 2016-09-30$237.6kus-gaap:Revenues
Cost of revenue3 months2016-07-01 to 2016-09-30$90.5kus-gaap:CostOfRevenue
Cost of revenue6 months2016-04-01 to 2016-09-30$154.6kus-gaap:CostOfRevenue
Selling, general and administrative3 months2016-07-01 to 2016-09-30$339.6kus-gaap:SellingGeneralAndAdministrativeExpense
Selling, general and administrative6 months2016-04-01 to 2016-09-30$636.8kus-gaap:SellingGeneralAndAdministrativeExpense
Operating income3 months2016-07-01 to 2016-09-30−$549.6kus-gaap:OperatingIncomeLoss
Operating income6 months2016-04-01 to 2016-09-30−$933.2kus-gaap:OperatingIncomeLoss
Interest expense3 months2016-07-01 to 2016-09-30$51.4kus-gaap:InterestExpense
Interest expense6 months2016-04-01 to 2016-09-30$90.0kus-gaap:InterestExpense
Income tax3 months2016-07-01 to 2016-09-30$0us-gaap:IncomeTaxExpenseBenefit
Income tax6 months2016-04-01 to 2016-09-30$0us-gaap:IncomeTaxExpenseBenefit
Net income3 months2016-07-01 to 2016-09-30−$583.9kus-gaap:NetIncomeLoss
Net income6 months2016-04-01 to 2016-09-30−$998.0kus-gaap:NetIncomeLoss
Diluted EPS3 months2016-07-01 to 2016-09-30−$0.02us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2016-04-01 to 2016-09-30−$0.04us-gaap:EarningsPerShareDiluted
Basic EPS3 months2016-07-01 to 2016-09-30−$0.02us-gaap:EarningsPerShareBasic
Basic EPS6 months2016-04-01 to 2016-09-30−$0.04us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2016-07-01 to 2016-09-3023,636,403 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2016-04-01 to 2016-09-3023,636,403 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2016-04-01 to 2016-09-30−$676.7kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2016-04-01 to 2016-09-30$4.5kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2016-09-30$939.3kus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2016-09-30$2.9mus-gaap:AssetsCurrent
Total assetsAt period end2016-09-30$18.9mus-gaap:Assets
Current liabilitiesAt period end2016-09-30$2.9mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2016-09-30$4.0mus-gaap:Liabilities
Long-term debtAt period end2016-09-30$653.8kus-gaap:LongTermDebtNoncurrent
Shareholders' equityAt period end2016-09-30$14.4mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001185185-16-005839. Last ingested by Listed: Nov 6, 2026, 16:27 ET. Listed shows no prices and gives no investment advice.